Vaccinex(VCNX)
$1.000.00 (0.00%)
VCNX
Vaccinex financials statements
$1.00
At close:0.00 (0.00%)
Want to see VCNX full AI Analyst Report?
Vaccinex (VCNX) Ratios
304 Followers
Vaccinex Ratios
VCNX's free cash flow for Q4 2024 was $-3.93M. For the 2024 fiscal year, VCNX's free cash flow was increased by $0.00 and operating cash flow was $-3.93M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.45 | 0.50 | 0.57 | 2.95 | 4.17 |
| Quick Ratio | 0.45 | 0.50 | 0.57 | 2.95 | 4.17 |
| Cash Ratio | 0.04 | 0.22 | 0.26 | 2.52 | 3.81 |
| Solvency Ratio | -0.56 | -3.65 | -3.39 | -7.01 | -9.14 |
| Operating Cash Flow Ratio | -1.67 | -3.18 | -2.91 | -7.52 | -11.21 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -647.44 | -229.79 | -257.76 | -341.86 |
| Net Current Asset Value | $ -7.63M | $ -2.55M | $ -2.59M | $ 4.69M | $ 6.97M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 3.07 | 0.01 | 0.07 | 0.06 | 0.04 |
| Debt-to-Equity Ratio | -0.73 | -0.01 | -0.11 | 0.09 | 0.05 |
| Debt-to-Capital Ratio | -2.66 | -0.01 | -0.12 | 0.09 | 0.05 |
| Long-Term Debt-to-Capital Ratio | -2.66 | 0.00 | -0.01 | 0.02 | 0.02 |
| Financial Leverage Ratio | -0.24 | -1.04 | -1.57 | 1.54 | 1.33 |
| Debt Service Coverage Ratio | -39.37 | -686.59 | -259.84 | -257.97 | -24.24 |
| Interest Coverage Ratio | -39.64 | -9367.50 | -22885.00 | -9953.00 | -27.80 |
| Debt to Market Cap | 1.91 | 0.01 | 0.02 | 0.01 | 0.01 |
| Interest Debt Per Share | 2.11 | 0.01 | 0.53 | 2.41 | 8.78 |
| Net Debt to EBITDA | -1.03 | 0.06 | 0.07 | 0.30 | 0.38 |
| Profitability Margins | |||||
| Gross Profit Margin | 98.33% | 100.00% | 100.00% | 68.00% | 81.22% |
| EBIT Margin | -249.74% | -3100.17% | -3485.44% | -19813.00% | -2396.78% |
| EBITDA Margin | -248.07% | -3084.53% | -3464.56% | -19606.00% | -2378.00% |
| Operating Profit Margin | -249.74% | -3117.30% | -4014.91% | -19906.00% | -2498.89% |
| Pretax Profit Margin | -251.07% | -3100.50% | -3552.81% | -19815.00% | -2486.67% |
| Net Profit Margin | -251.07% | -3100.50% | -3552.81% | -19722.00% | -2486.67% |
| Continuous Operations Profit Margin | -251.07% | -3100.50% | -3552.81% | -19815.00% | -2486.67% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 99.53% | 100.00% |
| EBT Per EBIT | 100.54% | 99.46% | 88.49% | 99.54% | 99.51% |
| Return on Assets (ROA) | -292.38% | -717.80% | -557.73% | -247.24% | -227.37% |
| Return on Equity (ROE) | 69.29% | 748.95% | 876.29% | -379.78% | -301.94% |
| Return on Capital Employed (ROCE) | 252.27% | 753.01% | 1001.53% | -365.92% | -296.43% |
| Return on Invested Capital (ROIC) | 252.27% | 760.66% | 1108.77% | -350.58% | -288.26% |
| Return on Tangible Assets | -292.38% | -717.80% | -557.73% | -247.24% | -227.37% |
| Earnings Yield | -181.96% | -905.90% | -472.70% | -72.61% | -75.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.81 | 0.72 | 0.59 | 0.57 | 0.00 |
| Payables Turnover | 0.01 | 0.00 | 0.00 | 0.14 | 0.16 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 53.72 | 9.25 | 2.02 | 0.20 | 2.05 |
| Asset Turnover | 1.16 | 0.23 | 0.16 | 0.01 | 0.09 |
| Working Capital Turnover Ratio | -0.90 | -0.23 | 0.48 | 0.02 | 0.34 |
| Cash Conversion Cycle | -35965.06 | 508.94 | 615.38 | -2037.92 | -2291.51 |
| Days of Sales Outstanding | 201.23 | 508.94 | 615.38 | 638.75 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 36166.29 | 0.00 | 0.00 | 2676.67 | 2291.51 |
| Operating Cycle | 201.23 | 508.94 | 615.38 | 638.75 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.41 | -7.71 | -37.17 | -94.39 | -185.16 |
| Free Cash Flow Per Share | -2.41 | -7.72 | -37.31 | -94.88 | -185.39 |
| Dividend Paid and CapEx Coverage Ratio | -716.67 | -735.73 | -257.22 | -192.67 | -790.56 |
| Capital Expenditure Coverage Ratio | -716.67 | -735.73 | -257.22 | -192.67 | -790.56 |
| Operating Cash Flow Coverage Ratio | -1.17 | -647.44 | -69.77 | -39.33 | -64.87 |
| Operating Cash Flow to Sales Ratio | -3.08 | -26.93 | -30.24 | -190.74 | -28.11 |
| Free Cash Flow Yield | -223.44% | -787.96% | -403.84% | -70.59% | -84.89% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.55 | -0.11 | -0.21 | -1.38 | -1.33 |
| Price-to-Sales (P/S) Ratio | 1.38 | 3.42 | 7.52 | 271.60 | 33.16 |
| Price-to-Book (P/B) Ratio | -0.38 | -0.83 | -1.85 | 5.23 | 4.03 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.45 | -0.13 | -0.25 | -1.42 | -1.18 |
| Price-to-Operating Cash Flow Ratio | -0.45 | -0.13 | -0.25 | -1.42 | -1.18 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.00 | 0.00 | 0.03 | 0.03 |
| Enterprise Value Multiple | -1.59 | -0.05 | -0.15 | -1.08 | -1.01 |
| Enterprise Value | 8.27M | 974.97K | 3.00M | 21.25M | 21.64M |
| EV to EBITDA | -1.59 | -0.05 | -0.15 | -1.08 | -1.01 |
| EV to Sales | 3.95 | 1.62 | 5.26 | 212.54 | 24.05 |
| EV to Free Cash Flow | -1.28 | -0.06 | -0.17 | -1.11 | -0.85 |
| EV to Operating Cash Flow | -1.28 | -0.06 | -0.17 | -1.11 | -0.86 |
| Tangible Book Value Per Share | -2.84 | -1.19 | -4.98 | 25.70 | 54.25 |
| Shareholders’ Equity Per Share | -2.84 | -1.19 | -4.98 | 25.70 | 54.25 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.78 | 0.29 | 1.23 | 0.49 | 6.59 |
| Net Income Per Share | -1.97 | -8.88 | -43.68 | -97.59 | -163.80 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.00 | 1.02 | 1.00 | 1.04 |
| Research & Development to Revenue | 2.01 | 20.87 | 29.08 | 139.79 | 19.07 |
| SG&A to Revenue | 1.47 | 11.30 | 12.07 | 62.02 | 6.92 |
| Stock-Based Compensation to Revenue | 0.00 | 0.57 | 0.83 | 5.45 | 0.60 |
| Income Quality | 1.23 | 0.87 | 0.85 | 0.96 | 1.13 |
Currency in USD

